A pooled analysis of four randomized trials reported that elinzanetant, a dual neurokinin receptor antagonist, showed no liver toxicity or cancer signals over 52 weeks. Side effects were mostly mild early in treatment, supporting the emerging safety profile for the investigational hot-flash therapy. For women’s health and menopause care decision-making, the pooled duration and the specific absence of liver/cancer warnings are the key points. They provide additional reassurance in a class where long-term tolerability has been a recurring question. The dataset also provides trial-to-trial consistency signals that can influence formulary discussions and clinician confidence ahead of broader adoption.